We recently proposed a quantitative PCR procedure for the absolute measurement of c-erbB-2 oncogene amplification, based on the simultaneous polymerase chain reaction (PCR) amplification of the target gene and of a competitor DNA molecule acting as internal standard. To increase the number of assayable oncogenes and the accuracy of the quantitative comparison of gene amplification degree within the same tumor, we have now constructed a single synthetic competitor for int-2, c-myc, N-myc, epidermal growth factor receptor, and c-ethB-2 genes, and for the reference gene 3-globin. This competitor was constructed by a two-step recombinant PCR procedure and inserted as a 297-bp sequence in a plasmid. The order of primer insertion was designed to obtain competitors of comparable sizes to those of the respective genomic targets, but still easily recognizable from the latter ones by gel electrophoresis. The cloned competitor was tested to evaluate the linearity range for each assay. The present application of quantitative PCR based on a multiple competitor represents the first approach for the achievement of a single reagent for the evaluation of a panel of genes potentially amplified in human tumors.
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Regulatory and structural alterations of oncogenes appear to be one of the key events in the formation of most human cancers. Protooncogenes are present in all mammalian cells, where they play a role in normal growth and differentiation.
When activated (by point mutation, amplification, proviral insertion, or translocation), the same genes can contribute to cancer development (1) . In particular the presence of amplified oncogenes has been widely reported in human tumors, and in many cases a relation of amplification degree with clinical indicators was detected. Amplification of c-myc seems to correlate with poor prognosis in breast cancer (2) (3) (4) (5) and to be a prognostic marker in nodenegative patients (3, 4) . Also, in small-cell lung carcinoma, c-myc amplification is predictive of poor prognosis (6 neuroblastoma (7, 8) . The epidermal growth factor receptor (EGFr) is amplified in glioblastoma (9) , esophageal adenocarcinoma (10) , and some squamous carcinomas (11 )#{149}4 The c-erbB-2 (HER2/neu) oncogene is amplified in several tumors, including bladder (12, 13) , gastric (14) , renal (14) , salivary gland (15) , breast (16, 17) , and ovarian (17) carcinomas.
In these last two neoplasms c-erbB-2 amplification seems to be a prognostic index of clinical outcome (16, 17) . The int-2 oncogene is amplified in breast (18) , gastric (19) , and ovarian carcinomas (20) . Two oligonucleotides (oligo 1 and oligo 2, 168 and 165 nt, respectively) were synthesized to contain in oligo 1 the sequences of the first of the two primers of each pair in a tandem organization, whereas oligo 2 contains the sequences of the opposite strand primers. These oligonucleotides contain two complementary sequences of 36 nt at their 3' ends to allow the annealing of these tails followed by PCR amplification with primer pair int-2/1-ent-212(the two most external primers). The fragment so obtained (297 bp) was then cloned in the cloning site of the pCRll plasmid vector to obtain plasmid pONC (see Matenals and Methods).
Materials and Methods

Construction
The primer order is such that the sizes of the corresponding PCR products are comparable with those from genomic DNA, but still easily recognizable by PAGE.
flanking the vector polylinker. 
Assay Procedure
The assay procedure is substantially similar to the one previously described (23) and is based on two subsequent competitive PCR amplifications.
In the first, we determined the exact DNA concentration of each sample by taking a DNA aliquot of 20 ng (-6000
in the presence of the specific pairs of primers.
These competitor concentrations cover a hypothetical range of amplification of one-, three-, and ninefold.
If the equivalence between genomic and competitor DNA was not reached (i.e., if a sample was amplified more than ninefold), a subsequent PCR was then performed with less genomic DNA (3000 genome equivalents or less). The degree of oncogene amplification was deduced as described for the (3-globin gene. Linearity range was estimated for all six genes tested by pONC by adding to a fixed quantity of human genomic (G) normal DNA (5 ng) increasing amounts of competitor (C; from 120 to 60 000 pONC molecules). The densitometric ratio between competitor and genomic PCRproducts (C/Gratio) was evaluated by image analysis after PAGE and ethidium bromide staining and was plotted against the number of added molecules of pONC. To test whether this difference could lead to any bias in the precision of the PCR assay (which is based on the assumption that competitor and target amplify exactly with the same efficiency), we compared in a titration test, performed as described above, the results obtained by using pONC with those obtained by using two previously described competitor DNA fragments having the same sequence of the target genomic l3-globin and c-erbB-2 genes, except for a 20-nt insertion in the middle (23) . The results obtained with the 13-globin gene (Fig. 3) 
Results
Construction
10 (35) 4-30 (36) 3 (our data) [15] [16] [17] [18] [19] [20] (1) samples,
3(18)
and to obtain further evidence that the internal nucleotide composition of competitors has no effect on the results obtained,
we measured c-erbB-2 amplification in genomic samples (7 breast and 11 bladder carcinomas) with different amplification degrees of the c-erbB-2 gene, utilizing both the linear homologous competitor fragments (23) and the cloned heterologous competitor plasmid (pONC). The results obtained (see Fig. 4 tion is given in Fig. 5 , in which the results obtained by amplification of breast carcinoma DNA for f3-globin, c-myc, int-2, and c-erbB-2 genes are reported.
In this sample, amplification was detected both for c-erbB-2 (12-fold) and for c-myc (3.3-fold).
Discussion
By virtue of its sensitivity and specificity, PCR has broad fields of applications in different areas of the clinical laboratory.
PCR is widely applied in the study of neoplastic disorders, and the possibility of utilizing this technique to provide new prognostic markers has been recently reviewed (37) . 
